Intra-Cellular: Q4 Earnings Snapshot
By AP News
Published - Mar 01, 2023, 07:45 AM ET
Last Updated - Jun 22, 2023, 06:45 PM EDT
NEW YORK (AP) — NEW YORK (AP) — Intra-Cellular Therapies Inc. (ITCI) on Wednesday reported a loss of $44 million in its fourth quarter.
On a per-share basis, the New York-based company said it had a loss of 45 cents.
The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 62 cents per share.
The biopharmaceutical company posted revenue of $87.9 million in the period, also surpassing Street forecasts. Four analysts surveyed by Zacks expected $83.2 million.
